Special Issue

Novel Approaches to the Management of Patients with Gastrointestinal Tumors

Message from the Guest Editors

Cancers of the digestive system are major contributors to global cancer-associated morbidity and mortality. Although surgical resection remains the most common curative treatment for digestive cancers, the introduction of multimodal therapeutic approaches has improved the survival of many of these tumors. In addition, significant advancements in understanding the molecular biology underlying these tumors have provided novel therapeutic alternatives and unprecedented insights into the genetic drivers of tumor progression, the mechanisms of therapy resistance, the role of targeted therapies, especially immunotherapy, and the key role of cfDNA in providing prognostic information. In this Special Issue, we will focus on novel approaches to the management of patients with esophageal, gastric, and colorectal cancers. This may include TNT approaches, the pharmacological management of these malignancies, including chemo-, targeted, and immunotherapy, innovative therapeutic strategies such as CAR-T cell therapy or novel antibodydrug conjugates, and the impact of artificial intelligence, the microbiome or omics on the design of alternative strategies.

Guest Editors

Dr. Javier Rodriguez

Department of Medical Oncology, Clínica Universidad de Navarra, Pamplona, 31008 Navarra, Spain

Dr. Ignacio Matos García

Department of Medical Oncology, Gastrointestinal Unit, Cancer Center Clínica Universidad de Navarra, Madrid, Spain

Deadline for manuscript submissions

15 March 2026



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/236814

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

